Belgian protein biomarker firm Pronota said this week it has signed an agreement with Molecuence Corporation – a wholly owned subsidiary of Mitsubishi Chemical – to discover and validate protein biomarkers in stroke.

Pronota will use its proprietary biomarker discovery platform MASStermind and verification platform MASSterclass on the project, the financial terms of which were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.